Group Radstake

Research interest

To provide better and cheaper healthcare for patients with a chronic inflammatory disease a better understanding of the underlying molecular pathways driving these conditions is trivial. Despite extensive research over the past years, still approximately 90% of our drugs fail in more than 60% of the patients with chronic inflammation. Hence, there is a great unmet need to better understand these conditions and develop effective therapies – in other words – to know who to treat with what and for how long: so-called personalized medicine.

We apply a Systems Medicine approach to identify those molecular pathways that cause chronic inflammatory diseases but also to be able to achieve disease interception, prediction of mode of action, prognosis and therapy response.

Within the Systems Medicine approach we focus on isolated immune cell subsets to which we apply multiple OMICS layers after which computational modeling is used to integrate thes extensive data sets.

Molecular candidates arising from the Systems approach are then taken further in Proof-of-Concept and Proof-of-Mechanism studies using Ex vivo experimentation, disease in a dish models and experimental models of inflammation.

Key publications

  1. Kuiper J, Rothova A, de Boer J, Radstake TRDJ. The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers. Progress in Retinal and Eye Research. 2014 Dec (Invited review) IF 9.9. View publication
  2. van Bon L, Cossu M, Loof A, Gohar F, Wittkowski H, Vonk M, Roth J, van den Berg W, van Heerde W, Broen JC, Radstake TRDJ. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis. 2014 Aug;73(8):1585-9. IF 9.7. View publication
  3. Audia S, Rossato M, Santegoets K, Spijkers S, Wichers C, Bekker C, Bloem A, Boon L, Flinsenberg T, Compeer E, van den Broek T, Facy O, Ortega-Deballon P, Berthier S, Leguy-Seguin V, Martin L, Ciudad M, Samson M, Trad M, Lorcerie B5, Janikashvili N, Saas P, Bonnotte B, Radstake TRDJ. Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. Blood. 2014 Oct 30;124(18):2858-66. IF 9.4. View publication
  4. L. van Bon, A.J. Affandi, J. Broen, R.B. Christmann, R.J. Marijnissen, L. Stawski, G.A. Farina, G. Stifano, A.L. Mathes, M. Cossu, M. York, C. Collins, M. Wenink, R. Huijbens, R. Hesselstrand, T. Saxne, M. DiMarzio, D. Wuttge, S.K. Agarwal, J.D. Reveille, S. Assassi, M. Mayes, Y. Deng, J.P.H. Drenth, J. de Graaf, M. den Heijer, C.G.M. Kallenberg, M. Bijl, A. Loof, W.B. van den Berg, L.A.B. Joosten, V. Smith, F. de Keyser, R. Scorza, C. Lunardi, P.L.C.M. van Riel, M. Vonk, W. van Heerde, S. Meller, B. Homey, L. Beretta, M. Roest, M. Trojanowska, R. Lafyatis, Radstake TRDJ. Proteome-wide analysis identifies the chemokine CXCL4 as a clinical marker that drives critical pathological events in systemic sclerosis. New England Journal of Medicine 2014 Jan 30;370(5):433-43. IF 54.2. View publication
  5. Radstake TRDJ, Olga Gorlova, Blanca Rueda, Jose-Ezequiel Martin, Behrooz Z Alizadeh, Rogelio Palomino-Morales, Marieke J Coenen, Madelon C Vonk, Alexandre E Voskuyl, Annemie J Scheurwegh, Jasper C Broen, Piet L C M van Riel, Ruben van ‘t Slot, Annet Italiaander, Roel A Ophoff, Gabriela Riemekasten, Nico Hunzelmann, Carmen P Simeon, Norberto Ortego-Centeno, Miguel A González-Gay, María F González-Escribano, Spanish Scleroderma Group, Paolo Airo, Jaap van Laar, Ariane Herrick, Jane Worthington, Roger Hesselstrand, Vanessa Smith, Filip de Keyser, Fredric Houssiau, Christopher I Amos, Fredrick M Wigley, Laura Hummers, J Lee Nelson, Sandeep K Agarwal, Shervin Assassi, Pravitt Gourh, Filemon K Tan, Bobby P C Koeleman, Frank C Arnett, Javier Martin, Maureen D Mayes. Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics 2010; May;42(5):426-9. View publication


UMC Utrecht translational research